The global single-cell genome sequencing (SCGS) market size was valued at USD 730.53 million in 2016. It is anticipated to register a CAGR of 14.6% over the forecast period. Increasing R&D activities, rising incidence of chronic & severe immune system disorders and cancer, and growing focus of companies on product development are among the key trends triggering market growth. Moreover, supportive government policies are expected to boost the progress of the market over the forecast period.
Technological advancements in the field of single-cell genome sequencing are playing an instrumental role in the development of the market. Recently, Bio-Rad Laboratories, Inc. and Illumina, Inc. collaborated to develop an innovative workflow for SCGS analysis. They recently announced the launch of SCGS solution. The technologically advanced platforms offer intuitive analysis software solutions and are cost-effective in nature.
Moreover, supportive government policies are expected to boost the progress of the market over the forecast period. Rising number of genomics centers is also estimated to drive the market. Various established centers are working and eventually accelerating advancements through collaborative activities.
Various participants including Qiagen and Illumina, Inc. are developing and manufacturing NGS-based platforms and tools, such as SCGS-related bioinformatics and sampling, in order to address the surging demand for rapid and efficient sequencers. NGS platform allows parallel sequencing of multiple targeted genomic regions in various samples to detect concomitant mutations simultaneously, which can deal with maximal tumor genomic assessment.
Recently, investigators at the Harvard University developed novel approaches such as in Drop & Drop-Seq. These methods are developed for isolation of thousands of cells and sequencing preparation. Moreover, academic and commercial investigators are consistently pushing boundaries & gradually shaping the outlook of the genomics sector.
Instruments accounted for the largest revenue share in 2016. Development and implementation of technologically advanced instruments and solutions are projected to drive the growth of the segment in the near future. For instance, C1 system allows preparation of templates for DNA sequencing, mRNA sequencing, miRNA expression, or epigenetics. This C1 system allows simultaneous isolation, lysis, staining, neutralization, and whole genome amplification of up to 96 cells. It offers unbiased amplification and allows genomes to be represented properly with higher uniformity & reproducibility. The segment will maintain its dominance until 2025, expanding at the highest CAGR during the forecast period.
NGS is likely to be the fastest growing technology segment in the market. The growth of the segment can be attributed to extensive R&D activities and a wide range of applications in cancer-related investigations. Genome sequencing involves gene isolation, whole-genome amplification & construction, and finally sequencing of DNA. Researchers have developed combinatorial indexed sequencing tools that find application in clinics, guiding targeted therapies, and noninvasive monitoring.
In addition, microarray enables quantification of thousands of genes by hybridization of biological samples to an array, which carries thousands of synthetic oligonucleotides probes. However, after the arrival of the NGS technology, use of microarray systems has decreased. Several companies such as Illumina, Inc. are engaged in providing advanced microarray systems for SCG applications.
Moreover, multiple displacement amplification (MDA) is the most widely used process for whole-genome amplification prior to SCGS. Various studies have demonstrated the proof-of-principle of eWGA with MDA. This easy-to-operate method enables researchers to simultaneously detect copy number variations (CNVs) and single nucleotide polymorphism (SNPs) in an individual human cell and significantly improves amplification accuracy and uniformity.
Recent developments have created new opportunities to quantify mutation rates, identify rare cell types, characterization of intra-tumor cellular heterogeneity, and guide diagnosis & treatment. SCG analysis is also used for reconstruction of tissues in multicellular organisms.
Fluidigm is one of the leading players that provides SCGS-based techniques and technologies. Fluidigm developed complex microfluidics systems and used it for single-cell oriented studies. In addition, entities such as Illumina, Inc. and 10x Genomics are actively engaged in developing advanced genome analysis platforms.
Furthermore, development of microfluidic devices is leading to integration of steps involved in sequencing sample preparation and library generation for up to 96 samples. These systems can also reduce the DNA input requirements by 100 folds while improving data handling. Use of completely integrated sample preparation systems, based on lab-on-chip methods, overcome technical barriers to enable broader utilization of genomics across translational and basic investigational applications.
Cancer commanded the dominant share in the single cell genome sequencing market in 2016. Increasing incidence of prostate, colorectal, and breast cancer is poised to create lucrative growth opportunities. According to WHO, around 8.8 million deaths were reported in 2015 due to different types of cancers.
In addition, initiatives by various organizations such as the American Cancer Society & Breast Cancer Organization are also anticipated to boost growth. For instance, the American Cancer Society has approved funding of USD 39 million for cancer research and training. Such funding is expected to facilitate technological advancements in cancer research and diagnosis.
Circulating cells represented the leading share in the market in 2016. Widening clinical applications of circulating tumor cells (CTCs) as a biomarker for cancer detection is supplementing the growth of the segment. Furthermore, various investigations proved that a cell-free DNA exhibits a good representation of tumor genome in lung cancer and late-stage gastric cancer. When cell-free DNA is sequenced with tumor origin, it identifies biomarkers associated with the tumor, which helps determine molecular pathology.
In addition, they are also used for genomic profiling of sequence mutations or copy in disseminated tumor cells and CTCs. Such studies in the area are estimated to stimulate the growth of the market over the forecast period. It also aids in accurate diagnosis of the condition.
Academic & research labs are projected to be the highest revenue contributor throughout the forecast period. The dominance of the segment can be attributed to rising genomic centers and ongoing investigations in this field. Several genomic centers are engaged in exploring genome, transcriptome, and epigenome of single cell to understand disease pathology and its progression. Organization also provide high-throughput isolation and sequence library preparation services.
Government and various private organizations provide funding for advancements in this field. In addition, the presence of a large number of research facilities, especially in developed countries, is likely to augment the market over the forecast period. Usage of sequencing kits to understand the morphology and functioning of several roles of genes in various chronic conditions are anticipated to drive the demand for single cell genome sequencing in the coming years.
North America was at the forefront of the market in 2016, with the U.S. being the key revenue contributor. Some factors responsible for the dominance of this region are mounting cases of cancer, immunological disorders, and neuropsychiatric diseases coupled with technological advancements brought about by entities operating in the region.
Moreover, increasing investigations in genomics are poised to trigger the growth of the market over the forecast period. For instance, research on microfluidic droplet barcoding at ultra-high-throughput analyzed distributions of phage sequences, antibiotic resistance genes, and virulence factors in microbial communities from an environmental sample. Researchers at the University of California conducted this study.
However, Asia Pacific is anticipated to emerge as the fastest growing segment owing to increasing R&D expenditure in the field. Moreover, adequate administration support and collaborations among entities in Asian countries are also expected to bolster the growth of the regional market.
Furthermore, there are several studies being carried out with respect to multiple displacement amplification for genome amplification. According to researchers at the Waseda University, this method allows whole genome amplification of both cancer as well as single bacterial cells. These research activities are expected to escalate the growth of the market over the forecast period.
Major players in the market include Bio-Rad Laboratories; 10x Genomics; Novogene; Fluidigm; BGI; Illumina, Inc.; Oxford Nanopore Technologies; Pacific Biosciences; Thermo Fisher Scientific, Inc.; QIAGEN; and F Hoffmann-La Roche Ltd.
Currently, key players are forming partnerships with other market players in order to enhance their product portfolios. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.
For instance, in January 2017, Illumina, Inc. in association with Bio-Rad launched single cell genome sequencing solution. This launch is estimated to benefit researchers to investigate the role of individual cellular organelles in disease progressions, therapeutic response, and tissue function. Apart from this, in February 2016, Qiagen announced its collaboration with 10x Genomics, Inc. The two entities entered into co-marketing and co-development agreement to develop integrated workflow solutions for the market.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, Japan, China, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the global single-cell genome sequencing market report on the basis of product, technology, workflow, disease area, application, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Workflow Outlook (Revenue, USD Million, 2014 - 2025)
Disease Area Outlook (Revenue, USD Million, 2014 - 2025)
Application Outlook (Revenue, USD Million, 2014 - 2025)
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Academic & Research Laboratories
Biotechnology & biopharmaceutical companies
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East and Africa (MEA)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.